- Breast Cancer Evolution During Neoadjuvant Systemic Therapy — Recruiting • Oncology • NCT06681064.
- What is being tested: BELIEVE is a translational study collecting breast cancer tissue, blood, and imaging samples from patients receiving neoadjuvant systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) to understand how tumours evolve and respond during treatment before surgery.
- Patient eligibility overview: The study recruits individuals diagnosed with breast cancer who are scheduled to undergo systemic therapy prior to surgical intervention, with additional biological samples and MRI imaging obtained at specified timepoints during their treatment course.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. The samples collected from this study will be used for molecular and genetic research to understand why some cancers respond very well to anticancer treatments, and some do not, develop novel ways of accurately measuring response during treatment, as well as identify…
- : 1. Histologically confirmed non-metastatic invasive breast cancer. 2. Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy. 3. If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy. 4. Be aged 18 years and over. 5. Have given written informed consent to participate.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.